{"title":"smith&nephew收购Healthpoint生物疗法，进入快速增长的生物活性伤口护理领域","authors":"Heather Cartwright","doi":"10.3833/pdr.v2012i12.1860","DOIUrl":null,"url":null,"abstract":"In order to move into the fast-growing bioactive wound care market, Smith & Nephew (S&N) has agreed to acquire substantially all the assets of Healthpoint Biotherapeutics for US$782 M in cash. A key driver of the deal is Collagenase Santyl®, the only US FDA approved enzymatic debrider that S&N itself used to market. The company will also gain strong commercial capabilities in the US and a pipeline led by HP802-247, which is in Phase III development for venous leg ulcers and offers significant upside potential.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"21 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Smith & Nephew Moves into Fast-Growing Bioactive Wound Care Segment with Healthpoint Biotherapeutics Acquisition\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/pdr.v2012i12.1860\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In order to move into the fast-growing bioactive wound care market, Smith & Nephew (S&N) has agreed to acquire substantially all the assets of Healthpoint Biotherapeutics for US$782 M in cash. A key driver of the deal is Collagenase Santyl®, the only US FDA approved enzymatic debrider that S&N itself used to market. The company will also gain strong commercial capabilities in the US and a pipeline led by HP802-247, which is in Phase III development for venous leg ulcers and offers significant upside potential.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"21 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-12-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/pdr.v2012i12.1860\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/pdr.v2012i12.1860","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Smith & Nephew Moves into Fast-Growing Bioactive Wound Care Segment with Healthpoint Biotherapeutics Acquisition
In order to move into the fast-growing bioactive wound care market, Smith & Nephew (S&N) has agreed to acquire substantially all the assets of Healthpoint Biotherapeutics for US$782 M in cash. A key driver of the deal is Collagenase Santyl®, the only US FDA approved enzymatic debrider that S&N itself used to market. The company will also gain strong commercial capabilities in the US and a pipeline led by HP802-247, which is in Phase III development for venous leg ulcers and offers significant upside potential.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
